title: [Evaluation of 31 cases treated with bevacizumab-based chemotherapy].
abstract: The combination of bevacizumab and standard chemotherapy prolongs progression-free survival and improves response rates in advanced nonsquamous non-small-cell lung cancer(NSCLC). We evaluated the efficacy and safety of bevacizumab based chemotherapy in 31 cases of NSCLC. Adverse events occurred in all patients. Grade≥3 hematotoxicities were seen in 27 patients(87. 0%). Grade≥3 non-hematotoxicities were seen in 13 patients(41. 9%). Bevacizumab-related adverse events included epistaxis(74. 2%), hypertension(22. 6%), and proteinuria(22. 6%). Hemoptysis was reported in 9 patients( 29. 0%), but there was no pulmonary hemorrhage or severe hemoptysis. The treatment results of the 18 patients were evaluated as followes: partial response(PR)10, stable disease(SD)7, and progressive disease(PD)1 patient. The response rate(CR+PR)and disease control rate(CR+PR+SD)were 55. 6%and 94. 4%, respectively. The response rates were 66. 7%, 50. 0%, and 57. 1% for 1st-line(6 patients), 2nd-line and later(12 patients), and postoperative recurrence(7 patients all after 2nd-line)patients, respectively. Bevacizumab-based chemotherapy is an efficacious and safe treatment for advanced nonsquamous NSCLC.
authors.affiliation: Dept. of Respiratory Surgery, Kyoto Katsura Hospital, Japan.
authors.forename: Naoki
authors.initials: N
authors.lastname: Yamashita
authors.forename: Koji
authors.initials: K
authors.lastname: Takahashi
authors.forename: Keiji
authors.initials: K
authors.lastname: Ohata
authors.forename: Kenji
authors.initials: K
authors.lastname: Okita
authors.forename: Shinya
authors.initials: S
authors.lastname: Ito
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoshimura
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hanawa
authors.forename: Noriko
authors.initials: N
authors.lastname: Fujita
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab